Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer

Anshu Giri, Simrit S. Walia, Ajeet Gajra

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC. Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC. Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.

Original languageEnglish
Pages (from-to)297-305
Number of pages9
JournalRecent Patents on CNS Drug Discovery
Issue number4
StatePublished - Aug 1 2016


  • Antineoplastic Agents/therapeutic use
  • Carcinoma, Non-Small-Cell Lung/drug therapy
  • Cell Cycle Checkpoints/drug effects
  • Humans
  • Immunotherapy
  • Lung Neoplasms/drug therapy
  • Programmed Cell Death 1 Receptor


Dive into the research topics of 'Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this